Mobia Medical Q2 Revenue Doubles to $13.5M, Guides FY26 to $54-56M, Discloses Material Weakness
MOBI sits 22% above its 52-week low of $10.34.
Summary
Mobia Medical reported Q2 2026 revenue of $13.5 million, more than doubling from a year ago, and guided full-year revenue to $54-56 million. The company also disclosed a material weakness in its internal controls over financial reporting.
Key Events · Earnings and Guidance · MOBI
-
Q2 Revenue Doubles
Revenue reached $13.5 million in Q2 2026, up 102% from $6.7 million in Q2 2025, driven by higher Vivistim System adoption.
-
Full-Year Guidance Raised
Management guided full-year 2026 revenue to $54-56 million, implying continued strong growth for the remainder of the year.
-
Material Weakness Disclosed
The company reported a material weakness in internal control over financial reporting related to the calculation of net loss per share, which could lead to misstatements if not remediated.
-
IPO Resolves Going Concern
The May 2026 IPO provided $134 million in net proceeds, eliminating the going-concern doubt that existed in prior periods. Cash stood at $177.1 million as of June 30, 2026.
Analysis · MOBI · Industrial Applications And Services
Mobia Medical's Q2 revenue more than doubled year-over-year to $13.5 million, with gross margins holding at 83.2%. The company guided full-year 2026 revenue to $54-56 million, implying continued strong growth. However, the 10-Q also discloses a material weakness in internal controls over financial reporting related to the net loss per share calculation — a governance red flag that warrants attention. The IPO in May 2026 brought in $134 million net, resolving prior going-concern doubts and leaving the company with $177 million in cash. While the top-line momentum is impressive, the control deficiency tempers the positive signal.
At the time of this filing, MOBI was trading at $12.58 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $418.3M. The 52-week trading range was $10.34 to $15.29. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.